#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cerebral arteriovenous malformation haemorrhagic Chronic lymphocytic leukaemia refractory Myeloid leukaemia Indolent systemic mastocytosis Heavy menstrual bleeding Thymic carcinoma Antiphospholipid antibodies Aicardi-Goutieres syndrome Measles Andersen-Tawil syndrome Congenital disorder of glycosylation Anal cancer recurrent Alagille syndrome Frontotemporal dementia Multiple system atrophy More trials…

    Learn about Rare Diseases

    Ewing’s sarcoma recurrent Atypical haemolytic uraemic syndrome – Treatment Sarcoma – Treatment Haemophilia A with anti factor VIII Pituitary-dependent Cushing’s syndrome MELAS syndrome – Diagnostics Factor VIII deficiency – Diagnostics Erdheim-Chester disease – Diagnostics Primary immunodeficiency syndrome – Treatment Antithrombin III deficiency – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Elraglusib Dexamethasone Codeine Phosphate Ly3537982 Rosnilimab Jab-21822 Gad20-209-Fsp-A2 ULIXERTINIB Romosozumab Monalizumab Estradiol Hemihydrate Tiotropium Bromide Specific Nucleic Acid Sna-Ebv Ebastine Zipalertinib ALLERGEN EXTRACTS SAR445399 Minocycline Eptacog Alfa (Activated) Dnth103 More therapies…

    Learn about Your Condition

    Supranuclear palsy Breast cancer recurrent Nephroblastoma Peripheral artery angioplasty Oesophagectomy Colon cancer metastatic Tetanus Vascular calcification Incontinence Myelofibrosis Micrographic skin surgery Small intestine leiomyosarcoma Kaposi's sarcoma Bronchiolitis Hepatic cancer More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Migraine without aura

  • Study on the Long-Term Safety of Rimegepant for Treating Acute Migraine in Children and Adolescents Aged 6 to 17 Years

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Migraine with aura
    • Migraine without aura
    • Migraine
    Investigated Drugs:
    • Rimegepant
    Poland Spain

  • Study on Rimegepant for Treating Acute Migraine in Children and Adolescents Aged 6 to 17 Years

    Recruiting

    3 1 1
    Investigated Diseases:
    • Migraine with aura
    • Migraine without aura
    • Migraine
    Investigated Drugs:
    • Rimegepant
    Poland Spain Sweden

  • Study on the Effectiveness of High-Flow Oxygen Therapy for Migraine Attacks in Emergency Department Patients

    Recruiting

    2 1 1
    Investigated Diseases:
    • Migraine without aura
    Investigated Drugs:
    • Oxygen
    France

  • Study on the Safety and Effectiveness of Atogepant for Preventing Episodic Migraine in Children and Teens Aged 6 to 17

    Recruiting

    3 1
    Investigated Diseases:
    • Migraine with aura
    • Migraine without aura
    • Migraine
    Investigated Drugs:
    • Atogepant
    Belgium Denmark France Hungary Italy The Netherlands +4

  • Study on Long-term Safety and Tolerability of Atogepant for Children and Teens (Ages 6-17) with Migraine

    Recruiting

    3 1 1
    Investigated Drugs:
    • Atogepant
    Belgium Denmark France Hungary Italy The Netherlands +5

  • Study of apremilast‑induced headache and migraine in women with migraine without aura

    Not yet recruiting

    1 1 1
    Investigated Diseases:
    • Migraine without aura
    Investigated Drugs:
    • Apremilast
    Denmark
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!